Jim Cramer Sees Eli Lilly As More Than A 'One-Trick Pony' After FDA Advisors Back Its Alzheimer's Drug: 'It's Ultimately Headed To A Trillion Dollar Valuation'
Jim Cramer has expressed his confidence in Eli Lilly, LLY, citing the company’s diverse drug portfolio and the recent endorsement of its Alzheimer’s treatment by FDA advisors.
